Prednisone

Concomitant use may cause hypokalemia and has been associated with cardiac enlargement and congestive heart failure. Close monitoring required.

Concomitant use with corticosteroids can cause hypokalemia and has been associated with cardiac enlargement and congestive heart failure. Patients should be observed closely for hypokalemia.

May produce severe weakness in patients with myasthenia gravis. Should be withdrawn at least 24 hours before initiating corticosteroid therapy.

Both agents lower seizure threshold; concurrent use requires extreme caution with low initial dosing and gradual increases.

Concomitant use may increase risk of tendon rupture, especially in elderly patients. Rupture can occur during or after treatment.

Increased activity of both drugs may occur with concurrent use. Convulsions have been reported with this combination.

Patients on digitalis glycosides are at increased risk of arrhythmias due to corticosteroid-induced hypokalemia.

Potassium-depleting agents administered with corticosteroids require close observation for development of hypokalemia.

Concomitant use may increase risk of tendon rupture, especially in elderly patients. Rupture can occur during or after treatment.

Concurrent use with corticosteroids may produce severe weakness in patients with myasthenia gravis. Should be withdrawn 24 hours before initiating therapy if possible.

Concurrent use with corticosteroids may produce severe weakness in patients with myasthenia gravis. Should be withdrawn 24 hours before initiating therapy if possible.

Somatropin inhibits conversion of prednisone to its active metabolite. Patients may require increased maintenance or stress doses.

Prednisone may increase clearance of high-dose chronic aspirin, leading to decreased salicylate levels or increased toxicity upon withdrawal. Use cautiously in hypoprothrombinemia.

Corticosteroids may increase blood glucose concentrations, requiring dosage adjustments of antidiabetic medications.

May lead to loss of corticosteroid-induced adrenal suppression.

CYP 3A4 enzyme inducers enhance metabolism of corticosteroids, requiring increased prednisone dosage.

CYP 3A4 enzyme inducer enhances metabolism of corticosteroids, requiring increased prednisone dosage.

Cholestyramine may increase the clearance of corticosteroids, potentially reducing prednisone effectiveness.

Induces hepatic metabolism of corticosteroids, requiring increased prednisone dosage.

induce barbiturates, phenytoin, carbamazepine, rifampin inhibit ketoconazole, itraconazole, ritonavir, indinavir, macrolide antibiotics such as erythromycin indinavir, erythromycin Ketoconazole Ketoconazole has been reported to decrease the metabolism of certain corticosteroids by up to 60%, leading to increased risk of corticosteroid side effects.

Estrogens may decrease hepatic metabolism of corticosteroids, thereby increasing their effect.

induce barbiturates, phenytoin, carbamazepine, rifampin inhibit ketoconazole, itraconazole, ritonavir, indinavir, macrolide antibiotics such as erythromycin indinavir, erythromycin Ketoconazole Ketoconazole has been reported to decrease the metabolism of certain corticosteroids by up to 60%, leading to increased risk of corticosteroid side effects.

Serum concentrations of isoniazid may be decreased by concurrent corticosteroid use.

induce barbiturates, phenytoin, carbamazepine, rifampin inhibit ketoconazole, itraconazole, ritonavir, indinavir, macrolide antibiotics such as erythromycin indinavir, erythromycin Ketoconazole Ketoconazole has been reported to decrease the metabolism of certain corticosteroids by up to 60%, leading to increased risk of corticosteroid side effects.

Drugs which inhibit CYP 3A4 (e.g., ketoconazole, itraconazole, ritonavir, indinavir, macrolide antibiotics such as erythromycin ) have the potential to result in increased plasma concentrations of corticosteroids. Ketoconazole Ketoconazole has been reported to decrease the metabolism of certain corticosteroids by up to 60%, leading to increased risk of corticosteroid side effects. In addition, ketoconazole alone can inhibit adrenal corticosteroid synthesis and may cause adrenal insufficiency during corticosteroid withdrawal.

SKYTROFA inhibits 11βHSD-1, reducing conversion of prednisone to active metabolites. Patients on glucocorticoid replacement may require increased maintenance or stress doses.

Macrolide antibiotics cause significant decrease in corticosteroid clearance, potentially increasing prednisone levels.

Concomitant use increases risk of gastrointestinal side effects.

Prednisone may enhance or diminish anticoagulant effects variably; coagulation indices should be monitored to maintain desired anticoagulant effect.

Estrogens in contraceptives may decrease hepatic metabolism of corticosteroids, thereby increasing their effect.

Induces hepatic enzymes and may increase clearance of prednisone, requiring increases in prednisone dose to achieve desired response.

CYP 3A4 enzyme inducer enhances metabolism of corticosteroids, requiring increased prednisone dosage.

CYP 3A4 enzyme inducer enhances metabolism of corticosteroids, requiring increased prednisone dosage.

induce barbiturates, phenytoin, carbamazepine, rifampin inhibit ketoconazole, itraconazole, ritonavir, indinavir, macrolide antibiotics such as erythromycin indinavir, erythromycin Ketoconazole Ketoconazole has been reported to decrease the metabolism of certain corticosteroids by up to 60%, leading to increased risk of corticosteroid side effects.

Concomitant use increases risk of gastrointestinal side effects.

SOGROYA may inhibit 11βHSD-1 and reduce serum cortisol concentrations, potentially requiring increased glucocorticoid maintenance or stress doses.

NGENLA may inhibit 11βHSD-1 and reduce serum cortisol concentrations. Patients on prednisone replacement for hypoadrenalism may require increased maintenance or stress doses.

May require dose adjustment as conversion to active metabolite is dependent on 11βHSD-1 activity, which is inhibited by tesamorelin-stimulated GH.

Inhibits metabolism of prednisone and decreases clearance, requiring dose titration to avoid steroid toxicity.

Corticosteroids usually inhibit warfarin response, although conflicting reports exist. Coagulation indices should be monitored frequently.

No clinically significant drug interactions observed when melphalan coadministered with bortezomib in combination with prednisone.

No dose adjustment needed when co-administered with montelukast sodium.

No dose adjustment needed when co-administered with montelukast sodium.

Thalidomide Co-administration with thalidomide should be employed cautiously, as toxic epidermal necrolysis has been reported with concomitant use. Thalidomide Co-administration with thalidomide should be employed cautiously, as toxic epidermal necrolysis has been reported with concomitant use.